Brought together here for easy access, explore all the press releases, presentations, reports, calls and webcasts DSM has published in the last decade on its financial results, Capital Markets Days and Shareholders' meetings.
You can also find an overview of all the financial and regulatory press releases disclosing price-sensitive inside information issued during the same period.
2 March, 2023
16 Feb, 2023
01 Nov, 2022
02 Aug, 2022
May 10th, 2022
03 May 2022
March 2nd, 2022
Febuary 15th, 2022
02 Nov
14 Sep
03 Sep
03 Aug
06 May
05 May
02 Mar
16 Feb
04 Nov
03 Nov
04 Aug
12 June
08 May
07 May
27 February
21 February
05 November
01 August
08 May
07 May
08 March
14 February
31 October
20 June
14 February
02 November
15 February
03 November
17 February
11 February
26 February
26 September
20 February
27 September
29 February
29 September
23 February
DSM is obliged by article 17 of the European Market Abuse Regulation to disclose price-sensitive inside information to the Dutch Authority for the Financial Markets (AFM) and to publish this information via a press release. Full details of the AFM's rules on the disclosure of inside information and relevant definitions can be found on their website.
Below are the financial and regulatory press releases published during the last decade. The AFM also maintains an independent public register of these press releases.
20 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
17 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
15 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
14 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
13 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
08 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
07 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
06 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
03 Mar 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
02 Mar 2023
Royal DSM, a global purpose-led, performance-driven leader in Health, Nutrition & Bioscience, today announces the publication of its 2022 Integrated Annual Report (IAR).
27 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
24 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
20 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
17 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 Feb 2023
DSM delivered a solid performance in 2022 against a background of continued global supply chain challenges and significantly higher energy and raw materials costs, consolidating the strong growth of 2021. Pricing actions to counter higher costs, supported top-line growth, however with a price-cost gap impacting near-term margins, especially in Animal, Nutrition & Health.
13 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
10 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
08 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
03 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
02 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
01 Feb 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
30 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
24 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 Jan 2023
DSM today held an Extraordinary General Meeting of Shareholders (EGM). The DSM Shareholders approved the proposed merger between DSM and Firmenich International SA (Firmenich) and voted in favour of all related resolutions as set out in the notice of the EGM.
20 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
19 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
18 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
17 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
13 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
12 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
11 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
10 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
09 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
06 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
05 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
04 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
03 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
02 Jan 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
30 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
29 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
27 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
20 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
19 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
15 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
13 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.
06 Dec 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.
01 Nov 2022
DSM’s trading update for the first nine months of 2022 is out now and our Health, Nutrition & Bioscience businesses all delivered good sales growth. Market demand remained resilient in what is a challenging macro-economic environment with the rising cost inflation.
02 Aug 2022
A good half year performance underpinned by resilient market demand.
02 Aug 2022
DSM announces that it pledges to purchase all of its electricity worldwide from renewable sources
28 Jun 2022
Royal DSM, a global purpose-led science-based company, today provides the investment community with comparative quarterly figures for 2021 and 2022 Q1.
31 May 2022
Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.
10 May 2022
Royal DSM, a global purpose-led science-based company, confirmed its resolution to declare a dividend for the financial year 2021 of €2.50 per ordinary share was passed today, 10 May 2022, at its Annual General Meeting of Shareholders.
10 May 2022
Royal DSM, a global purpose-led science-based company, today held its Annual General Meeting of Shareholders. All the resolutions on the agenda were approved by the shareholders.
10 May 2022
Royal DSM, a global purpose-led science-based company, has repurchased 40,085 of its own shares in the period from 2 May 2022 up to and including 6 May 2022 at an average price of €156.08.
03 May 2022
Royal DSM, a global purpose-led science-based company, has repurchased 157,671 of its own shares in the period from 25 April 2022 up to and including 29 April 2022 at an average price of €156.34.
26 Apr 2022
Royal DSM, a global purpose-led science-based company, has repurchased 142,403 of its own shares in the period from 18 April 2022 up to and including 22 April 2022 at an average price of €155.73.
20 Apr 2022
Royal DSM, a global purpose-led science-based company, has repurchased 101,258 of its own shares in the period from 11 April 2022 up to and including 15 April 2022 at an average price of €158.07.
12 Apr 2022
Royal DSM, a global purpose-led science-based company, has repurchased 173,491 of its own shares in the period from 4 April 2022 up to and including 8 April 2022 at an average price of €162.36.
05 Apr 2022
Royal DSM, a global purpose-led science-based company, has repurchased 171,521 of its own shares in the period from 28 March 2022 up to and including 1 April 2022 at an average price of €162.39.
04 Apr 2022
Royal DSM, a global purpose-led science-based company, today provides preliminary comparative financial figures for 2021 following the establishment of DSM’s Health, Nutrition & Bioscience (“HNB”) structure, which became effective as of 1 January 2022.
29 Mar 2022
Royal DSM, a global purpose-led science-based company, has repurchased 205,518 of its own shares in the period from 21 March 2022 up to and including 25 March 2022 at an average price of €160.28.
24 Mar 2022
The Bovaer® pilot collaboration between the Dutch companies FrieslandCampina, DSM, and Agrifirm marks an important step forward in increasing the sustainability of the dairy sector. Some 200 FrieslandCampina dairy farms in the Netherlands will take part in the pilot in the second half of 2022. Providing the results are positive, the use of Bovaer® will be further upscaled from 2023.
22 Mar 2022
Update March 22nd: DSM has repurchased 176,083 of its own shares in the period from 10 March 2022 up to and including 11 March 2022 at an average price of €150.87.
15 Mar 2022
DSM has repurchased 176,083 of its own shares in the period from 10 March 2022 up to and including 11 March 2022 at an average price of €150.87.
10 Mar 2022
Royal DSM, a global purpose-led science-based company, today announces the repurchase, starting 10 March 2022, of 1,330,000 ordinary shares.
02 Mar 2022
DSM publishes 2021 annual report on the company's social, environmental and financial performance for the year.
24 Feb 2022
Royal DSM, a global purpose-led science-based company, announces that European Union (EU) member states approved the marketing of the methane-reducing feed additive for dairy cows, Bovaer®, in the EU. After inclusion in the EU registry, expected in the coming weeks, it is the first time a feed additive authorised in the EU for environmental benefits can be marketed. This marks a significant milestone for DSM, paving the way for Bovaer® to revolutionize the dairy market.
15 Feb 2022
Strong financial growth alongside significant progress toward our sustainability and strategy ambitions made 2021 a year to be proud of.
19 Nov 2021
DSM has received a positive European Food Safety Authority (EFSA) opinion for the use of its novel methane-reducing feed additive for ruminants, Bovaer®, in the European Union. The EFSA opinion confirms that the feed additive reduces enteric methane emissions from dairy cows and is safe for the animal and the consumer.
09 Nov 2021
DSM is planning to realize large scale production capacity for its novel methane-reducing feed additive for ruminants, Bovaer® with a new plant at its existing site in Dalry, Scotland, supported by Scottish Enterprise.
02 Nov 2021
DSM delivers a very good nine months of the year.
19 Oct 2021
DSM acquires First Choice Ingredients, a leading supplier of dairy-based savory flavorings.
14 Sep 2021
Quantifiable commitments aim to address how the world produces and consumes food by 2030.
14 Sep 2021
DSM is simplifying its operating structure and reorganizing its Health, Nutrition & Bioscience activities into three Business Groups.
03 Sep 2021
DSM to acquire developer of clean label, fermented dairy and dairy-based savory flavorings for taste and functional solutions.
31 Aug 2021
DSM has completed the repurchase 250,000 shares announced on 9 August 2021 for a total consideration of €44.6 million.
24 Aug 2021
DSM repurchased 109,792 shares from 16 to 20 August 2021 at an average price of €178.66.
17 Aug 2021
DSM repurchased 80,268 shares from 9 to 13 August 2021 at an average price of €175.75.
09 Aug 2021
DSM will repurchase 250,000 ordinary shares to cover commitments for the interim stock dividend 2021.
03 Aug 2021
DSM accelerates its 30% greenhouse gas (GHG) emissions reduction target to 50% by 2030.
03 Aug 2021
DSM delivers very good first half year results, with full year outlook updated to reflect stronger Materials performance.
27 Jul 2021
DSM acquires biotech start-up Midori, developers of breakthrough eubiotics for more sustainable animal farming.
13 Jul 2021
DSM informs its stakeholders that CVC Capital Partners today announced the proposed sale of AOC.
17 Jun 2021
DSM has completed the repurchase of 800,000 of its own shares at an average price of €150.36.
16 Jun 2021
€500 million 1.375% bond originally due to mature in September 2022 redeemed early.
15 Jun 2021
DSM repurchased 66,456 shares from 7 to 11 June 2021 at an average price of €152.02.
08 Jun 2021
DSM repurchased 117,895 shares from 31 May to 4 June 2021 at an average price of €151.73.
03 Jun 2021
Sale completes divestment of all DSM’s solar activities.
01 Jun 2021
DSM repurchased 102,721 shares from 24 to 28 May 2021 at an average price of €151.13.
25 May 2021
DSM repurchased 126,930 shares from 17 to 21 May 2021 at an average price of €148.27.
19 May 2021
€500 million 1.375% bond issued 24 September 2015 to be redeemed earlier than scheduled.
18 May 2021
DSM repurchased 145,703 shares from 10 to 14 May 2021 at an average price of €147.94.
11 May 2021
DSM repurchased 192,978 shares from 3 to 7 May 2021 at an average price of €151.32.
06 May 2021
DSM declares a dividend for the 2020 financial year of €2.40 per ordinary share.
06 May 2021
DSM held a virtual Annual General Meeting of Shareholders on 6 May 2021 when shareholders approved all resolutions on the agenda.
05 May 2021
DSM delivers very good Q1 with sales +7% and adjusted EBITDA +13%, updates Outlook 2021 reflecting strong Materials recovery.
29 Apr 2021
Cancellation concludes reduction in share capital following share buyback program executed from 1 April 2019 to February 2020.
01 Apr 2021
Sale to Covestro agreed in September 2020 for an equity value of €1.6 billion has finalized today.
31 Mar 2021
DSM acquires business consisting of 7 bio-based intermediate products to add to existing Aroma Ingredients portfolio.
16 Mar 2021
DSM will repurchase 800,000 ordinary shares to cover commitments for the final stock dividend 2020.
11 Mar 2021
DSM to sell residual solar backsheet business to Worthen Industries, Inc. following the sale of its solar coatings business to Covestro.
04 Mar 2021
Supervisory Board appoints Thomas Leysen to succeed Rob Routs as Chair and proposes Corien M. Wortmann-Kool as a new member.
02 Mar 2021
DSM publishes 2020 annual report on the company's social, environmental and financial performance for the year.
16 Feb 2021
DSM posts solid results in a challenging COVID-19 environment, continues to make good progress on execution of long-term strategic plan.
20 Jan 2021
Chris Goppelsroeder to retire on 1 April 2021 with DSM's Co-CEO Dimitri de Vreeze stepping into the role.
04 Nov 2020
Webcast, extracts and supplementary videos from DSM's 2020 investor event.
03 Nov 2020
DSM reports a solid first nine months in a challenging COVID-19 environment, with a continuing robust performance in Q3.
08 Oct 2020
DSM’s Resins & Functional Materials businesses moved to discontinued operations with their agreed sale to Covestro AG.
02 Oct 2020
DSM acquires Erber's Biomin specialty animal nutrition and health & Romer Labs food/feed safety diagnostics businesses.
30 Sep 2020
DSM to sell its Resins & Functional Materials and associated businesses to Covestro AG for an Equity Value of €1.6 billion.
24 Sep 2020
DSM's Supervisory Board nominates Mrs. Carla Mahieu for appointment as a new Supervisory Board member at next AGM.
01 Sep 2020
DSM repurchased 27,328 shares from 24 to 28 August 2020 at an average price of €134.92.
25 Aug 2020
DSM repurchased 70,444 shares from 17 to 21 August 2020 at an average price of €131.13.
18 Aug 2020
DSM repurchased 102,228 shares from 7 to 14 August 2020 at an average price of €129.61.
07 Aug 2020
Repurchase of 200,000 ordinary shares equivalent to approximately €25 million on 6 August 2020.
04 Aug 2020
DSM reports a solid H1 2020 in a challenging COVID-19 environment, overall earnings outlook remains suspended.
17 Jun 2020
New bonds in two tranches of €500m allow DSM to lock-in low interest rates to finance the acquisition of the Erber Group.
12 Jun 2020
As prudent measure given Covid-19 environment and acquisition of Erber Group, DSM cancels remainder of €1 billion share buy-back program.
12 Jun 2020
DSM adds Erber Group’s mycotoxin risk and gut health performance management and food and feed safety diagnostic solutions to portfolio.
08 May 2020
DSM declares a dividend for the financial year 2019 of €2.40 per ordinary share.
08 May 2020
DSM held a virtual Annual General Meeting of Shareholders on 8 May 2020 when shareholders approved all resolutions on the agenda.
07 May 2020
DSM reports a solid Q1 2020, suspends overall earnings outlook given current limited visibility in Materials.
01 Apr 2020
DSM acquires world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.
24 Mar 2020
DSM repurchased 239,127 shares from 16 to 20 March 2020 at an average price of €89.77.
17 Mar 2020
DSM repurchased 705,494 shares from 9 to 13 March 2020 at an average price of €96.33.
10 Mar 2020
DSM repurchased 455,379 shares from 2 to 6 March 2020 at an average price of €106.13.
02 Mar 2020
DSM will repurchase 1,400,000 ordinary shares to cover share plans and stock dividend.
27 Feb 2020
2019 Integrated Annual Report on DSM's performance and progress during 2019 in terms of People, Planet and Profit published.
25 Feb 2020
Helen Mets appointed Executive Vice President Materials and member of the Executive Committee as of 1 March 2020.
25 Feb 2020
DSM repurchased 183,602 shares from 17 to 21 February 2020 at an average price of €115.01.
21 Feb 2020
DSM to acquire world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.
18 Feb 2020
DSM repurchased 80,423 shares from 10 to 14 February 2020 at an average price of €116.31.
13 Feb 2020
DSM delivered a good financial performance for the year and achieved the key milestones in the first year of its Strategy 2021.
11 Feb 2020
DSM repurchased 80,423 shares from 3 to 7 February 2020 at an average price of €113.07.
04 Feb 2020
DSM repurchased 195,502 shares from 27 to 31 January 2020 at an average price of €110.38.
28 Jan 2020
DSM repurchased 110,420 shares from 20 to 24 January 2020 at an average price of €111.85.
21 Jan 2020
DSM repurchased 213,886 shares from 13 to 17 January 2020 at an average price of €109.84.
20 Jan 2020
As Honorary Chairman Feike Sijbesma will continue to act as DSM's ambassador.
14 Jan 2020
DSM repurchased 225,888 shares from 6 to 10 January 2020 at an average price of €114.73.
07 Jan 2020
DSM repurchased 28,011 shares from 2 to 3 January 2020 at an average price of €116.83.
30 Dec 2019
DSM acquires specialty dairy solutions provider CSK (Koninklijke CSK Food Enrichment C.V.) for about €150 million.
24 Dec 2019
DSM repurchased 308,286 shares from 16 to 20 December 2019 at an average price of €115.95.
17 Dec 2019
DSM repurchased 347,955 shares from 9 to 13 December 2019 at an average price of €114.42.
10 Dec 2019
DSM repurchased 438,649 shares from 2 to 6 December 2019 at an average price of €114.60.
09 Dec 2019
Thomas Leysen nominated as new Supervisory Board member while Rob Routs, Eileen Kennedy & Pradeep Pant nominated for reappointment.
03 Dec 2019
DSM repurchased 284,636 shares from 25 to 29 November 2019 at an average price of €117.00.
02 Dec 2019
CEO Feike Sijbesma will hand over his responsibilities to Managing Board colleagues Geraldine Matchett and Dimitri de Vreeze as Co-CEO’s in February 2020.
26 Nov 2019
DSM repurchased 445,046 shares from 18 to 22 November 2019 at an average price of €116.60.
19 Nov 2019
DSM repurchased 428,180 shares from 11 to 15 November 2019 at an average price of €116.15.
18 Nov 2019
Acquisition strengthens dairy portfolio and application know-how and expertise, particularly in the areas of cheese taste, texture and bio-preservation.
12 Nov 2019
DSM repurchased 358,500 shares from 4 to 8 November 2019 at an average price of €114.17.
05 Nov 2019
DSM repurchased 196,255 shares from 28 October to 1 November 2019 at an average price of €107.26.
05 Nov 2019
DSM reports a good first nine months in 2019 with a solid performance in Q3.
29 Oct 2019
DSM repurchased 153,111 shares from 21 to 25 October 2019 at an average price of €106.73.
22 Oct 2019
DSM repurchased 190,019 shares from 14 to 18 October 2019 at an average price of €108.44.
15 Oct 2019
DSM repurchased 183,500 shares from 7 to 11 October 2019 at an average price of €107.03.
08 Oct 2019
DSM repurchased 212,170 shares from 30 September to 4 October 2019 at an average price of €107.78.
01 Oct 2019
DSM repurchased 162,212 shares from 23 to 27 September 2019 at an average price of €106.77.
24 Sep 2019
DSM repurchased 274,642 shares from 16 to 20 September 2019 at an average price of €108.43
17 Sep 2019
DSM repurchased 245,676 shares from 9 to 13 September 2019 at an average price of €113.21.
10 Sep 2019
DSM repurchased 131,289 shares from 2 to 6 September 2019 at an average price of €115.38.
03 Sep 2019
DSM repurchased 95,745 shares from 26 to 30 August 2019 at an average price of €110.88.
27 Aug 2019
DSM repurchased 168,100 shares from 19 to 23 August 2019 at an average price of €110.62.
27 Aug 2019
JV consists of vitamin E production facilities in Jingzhou and a minority shareholding in Nenter’s intermediates facility in Shishou, China.
20 Aug 2019
DSM repurchased 276,022 shares from 12 to 16 August 2019 at an average price of €108.76.
13 Aug 2019
DSM repurchased 263,977 shares from 5 to 9 August 2019 at an average price of €108.13.
06 Aug 2019
DSM repurchased 131,000 shares from 29 July to 2 August 2019 at an average price of €112.52.
01 Aug 2019
DSM reports a good H1 2019 and maintains the previously increased full year outlook.
16 Jul 2019
DSM repurchased 19,871 shares from 8 to 12 July 2019 at an average price of €109.81.
09 Jul 2019
DSM repurchased 41,213 shares from 1 to 5 July 2019 at an average price of €109.50.
02 Jul 2019
DSM repurchased 150,213 shares from 24 to 28 June 2019 at an average price of €108.69.
28 Jun 2019
DSM exercises right to redeem all the €300,000,000 1.75% Notes due on 13 November on first optional redemption date of 13 August 2019.
25 Jun 2019
DSM repurchased 94,194 shares from 17 to 21 June 2019 at an average price of €108.56.
18 Jun 2019
DSM repurchased 147,395 shares from 10 to 14 June 2019 at an average price of €106.02.
11 Jun 2019
DSM repurchased 206,267 shares from 3 to 7 June 2019 at an average price of €102.96.
04 Jun 2019
DSM repurchased 163,903 shares from 27 to 31 May 2019 at an average price of €100.64.
28 May 2019
DSM repurchased 284,500 shares from 20 to 24 May 2019 at an average price of €101.52.
21 May 2019
DSM repurchased 222,500 shares from 13 to 17 May 2019 at an average price of €99.97.
14 May 2019
DSM repurchased 494,782 shares from 6 to 10 May 2019 at an average price of €101.18.
13 May 2019
DSM to acquire leading player in the development, production and sale of specialty materials in India.
08 May 2019
DSM declares a dividend for the financial year 2018 of €2.30 per ordinary share.
08 May 2019
DSM held its Annual General Meeting of Shareholders on 8 May 2019. Shareholders approved all resolutions on the agenda.
07 May 2019
DSM repurchased 172,159 shares from 29 April to 3 May 2019 at an average price of €100.61.
07 May 2019
DSM reports a good start to the year and increases full year outlook.
30 Apr 2019
DSM repurchased 165,141 shares from 23 to 26 April 2019 at an average price of €101.54.
23 Apr 2019
DSM repurchased 123,006 shares from 15 to 18 April 2019 at an average price of €102.40.
16 Apr 2019
DSM repurchased 229,636 shares from 8 to 12 April 2019 at an average price of €101.48.
09 Apr 2019
DSM repurchased 144,066 shares from 1 to 5 April 2019 at an average price of €99.84.
03 Apr 2019
All seven members of the Executive Committee to purchase shares in Royal DSM by converting 50% of their gross STI's into ordinary shares.
26 Mar 2019
Shareholders to vote on Erica Mann's appointment, and Pauline van der Meer Mohr's re-appointment, as members of DSM's Supervisory Board.
18 Mar 2019
DSM increases shareholding in Andre Pectin, a leading specialty food ingredient producer of hydrocolloids to 75%.
14 Mar 2019
€1 billion buy back intended to reduce issued capital, plus a further repurchase of 2,600,000 shares to cover share plans and stock dividend.
13 Mar 2019
DSM’s targets assessed by Science Based Targets initiative to be in line with the level of decarbonization required to keep global temperature increase below 2° C.
08 Mar 2019
Report demonstrates DSM’s consistent progress as a growth company with ambitious business and sustainability efforts that creates People, Planet and Profit value.
01 Mar 2019
50/50 Joint Venture with Cargill will produce zero-calorie, great-tasting sweeteners through fermentation.
14 Feb 2019
DSM reports a very strong year, including a robust Q4 and increases dividend by 25% from €1.85 to €2.30 per ordinary share.
06 Feb 2019
At the time DSM's IPO was the biggest introduction in the history of the Amsterdam Stock Exchange.
04 Feb 2019
DSM will increase its shareholding in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a leading specialty food ingredient producer of hydrocolloids.
31 Jan 2019
Patricia Malarkey, most recently Head of Research & Development and member of the Executive Committee at Syngenta, will join DSM as Chief Innovation Officer and member of the Executive Committee.
29 Jan 2019
DSM will create a 75/25 joint venture with Nenter & Co., Inc., which will include all Nenter’s production and related assets for Vitamin E.
08 Nov 2018
Companies to produce highly sought-after molecules such as steviol glycosides Reb M and Reb D through fermentation.
31 Oct 2018
DSM reports another very good quarter and is confident in achieving full year outlook.
30 Oct 2018
DSM anticipates receiving about €200 million in cash in various steps in 2018 and 2019.
09 Oct 2018
DSM repurchased 209,327 shares from 1 to 5 October 2018 at an average price of €90.13, finalizing program to repurchase 1,100,000 shares for a total of €98.9 million.
02 Oct 2018
DSM repurchased 121,592 shares from 24 to 28 September 2018 at an average price of €91.88.
25 Sep 2018
DSM repurchased 69,638 shares from 17 to 21 September 2018 at an average price of €91.24.
18 Sep 2018
DSM repurchased 94,032 shares from 10 to 14 September 2018 at an average price of €88.38.
13 Sep 2018
DSM recognized among the DJSI leaders for 15 years running and held the number one position in the sector eight times.
11 Sep 2018
DSM repurchased 189,309 shares from 3 to 7 September 2018 at an average price of €88.16.
04 Sep 2018
DSM repurchased 117,471 shares from 27 to 31 August 2018 at an average price of €91.17.
28 Aug 2018
DSM repurchased 82,975 shares from 20 to 24 August 2018 at an average price of €89.58.
21 Aug 2018
DSM repurchased 215,656 shares from 13 to 17 August 2018 at an average price of €89.80.
13 Aug 2018
DSM intends to repurchase 1,100,000 ordinary shares: 500,000 to cover commitments under share-based compensation plans and 600,000 to cover part of the interim dividend 2018.
01 Aug 2018
DSM reports a very good H1 with strong performance across all businesses.
02 Jul 2018
Acquisition builds on partnership combining DSM’s unparalleled expertise in micronutrients with Mixfit technology.
29 Jun 2018
Bain Capital intends to acquire DSM Sinochem Pharmaceuticals, a DSM and Sinochem Group 50/50 joint venture, with the transaction expected to be completed in the fourth quarter of 2018 subject to customary regulatory approvals and consultations.
22 Jun 2018
DSM repurchased 324,894 shares from 15 to 20 June 2018 at an average price of €88.18, concluding program to repurchase 1,600,000 shares for a total of €136.7 million.
20 Jun 2018
With its unique science-based competences, DSM is ideally positioned to capture the growth opportunities offered by the global megatrends and Sustainable Development Goals (SDGs), with a particular focus on Nutrition & Health, Climate & Energy and Resources & Circularity.
15 Jun 2018
DSM repurchased 132,098 shares from 8 to 14 June 2018 at an average price of €89.07.
12 Jun 2018
DSM repurchased 141,033 shares from 1 to 7 June 2018 at an average price of €88.22.
01 Jun 2018
DSM repurchased 233,975 shares from 25 to 31 May 2018 at an average price of €86.30.
30 May 2018
DSM repurchased 176,500 shares from 18 to 24 May 2018 at an average price of €88.02.
30 May 2018
DSM has linked the interest rate of new €1 billion Revolving Credit Facility to its performance on the reduction of GHG emissions.
18 May 2018
DSM and CVC Capital Partners indirectly own 35% and 65% respectively of the shares of Fibrant BV through Chemicalnvest joint venture.
18 May 2018
DSM repurchased 91,500 shares from 14 to 17 May 2018 at an average price of €87.39.
09 May 2018
DSM declares a dividend for the financial year 2017 of €1.85 per ordinary share.
09 May 2018
DSM held its Annual General Meeting of Shareholders on 9 May 2018. Shareholders approved all resolutions on the agenda.
08 May 2018
Royal DSM issues its full Q1 2018 results, which are in line with the preliminary figures for Q1 2018 previously announced on 12 April 2018.
13 Apr 2018
DSM repurchased 88,350 shares from 6 to 12 April 2018 at an average price of €81.74.
12 Apr 2018
Continued strong organic sales growth in underlying business estimated at 11%. Adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind. Additional temporary vitamin price benefit estimated at €165m on Adjusted EBITDA. Overall very strong quarter with total Adjusted EBITDA up 55%.
06 Apr 2018
DSM repurchased 87,000 shares from 3 to 5 April 2018 at an average price of €80.10.
30 Mar 2018
DSM repurchased 188,000 shares from 23 to 29 March 2018 at an average price of €79.38.
23 Mar 2018
DSM repurchased 136,650 shares from 19 to 22 March 2018 at an average price of €80.59.
19 Mar 2018
DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under share based compensation plans and and part of the final dividend 2017.
01 Mar 2018
The 2017 Integrated Annual Report details the company's progress and performance over the year in terms of People, Planet and Profit.
14 Feb 2018
DSM again reports an excellent year, as it significantly exceeded its Strategy 2018 targets for EBITDA, ROCE and organic sales growth.
29 Dec 2017
Sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products finalized.
22 Dec 2017
DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year.
17 Nov 2017
DSM and Amyris enhance their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.
17 Nov 2017
DSM repurchased 151,900 shares from 10 to 14 November 2017 at an average price of €75.63, concluding program to repurchase 1,600,000 shares for a total of €109.3 million.
10 Nov 2017
DSM repurchased 243,624 shares from 3 to 9 November 2017 at an average price of €76.15.
02 Nov 2017
Strong performance in Q3 2017, contributing to very good first nine months.
09 Oct 2017
DSM repurchased 37,600 shares from 6 to 12 October 2017 at an average price of €69.54.
06 Oct 2017
DSM repurchased 140,692 shares from 29 September to 5 October 2017 at an average price of €69.52.
29 Sep 2017
DSM repurchased 163,310 shares from 22 to 28 September 2017 at an average price of €67.75.
25 Sep 2017
EBITDA and ROCE outlook for 2017 confirmed. DSM aims to continue to deliver against its strategic targets in 2018. DSM brings forward its regular strategic review process for the period beyond 2018 and expects to share the conclusions before the summer of 2018.
22 Sep 2017
DSM repurchased 117,424 shares from 15 to 21 September 2017 at an average price of €66.56.
22 Sep 2017
Twilmij’s core values, customer portfolio and solutions are a perfect fit with DSM’s ambitions in the animal nutrition & health market.
15 Sep 2017
DSM repurchased 128,851 shares from 8 to 14 September 2017 at an average price of €66.04.
08 Sep 2017
DSM repurchased 142,315 shares from 1 to 7 September 2017 at an average price of €65.01.
07 Sep 2017
DSM again named among worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index having been named among the global leaders for the past 14 years and holding the number one position in the sector seven times, including last year.
01 Sep 2017
DSM repurchased 188,430 shares from 25 to 31 August 2017 at an average price of €64.01.
29 Aug 2017
Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.
25 Aug 2017
DSM repurchased 185,837 shares from 18 to 24 August 2017 at an average price of €63.98.
18 Aug 2017
DSM repurchased 100,017 shares from 14 to 17 August 2017 at an average price of €63.21.
14 Aug 2017
DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under management and personnel option plans and for part of the interim dividend 2017.
01 Aug 2017
DSM maintained its positive momentum with a very strong first half-year performance with Q2 another very good quarter.
21 Jul 2017
Judith Wiese will join DSM as Executive Vice President Group People & Organization on 1 October 2017.
14 Jul 2017
DSM repurchased 261,898 shares from 7 to 13 July 2017 at an average price of €63.24, concluding program to repurchase 2,900,000 shares for a total of €187.2 million.
07 Jul 2017
DSM repurchased 218,403 shares from 30 June to 6 July 2017 at an average price of €63.72.
30 Jun 2017
DSM repurchased 182,175 shares from 23 to 29 June 2017 at an average price of €65.07.
23 Jun 2017
DSM repurchased 122,307 shares from 16 to 22 June 2017 at an average price of €67.16.
16 Jun 2017
DSM repurchased 123,435 shares from 9 to 15 June 2017 at an average price of €66.00.
09 Jun 2017
DSM repurchased 132,717 shares from 2 to 8 June 2017 at an average price of €65.73.
02 Jun 2017
DSM repurchased 123,673 shares from 26 May to 1 June 2017 at an average price of €66.16.
26 May 2017
DSM repurchased 123,847 shares from 19 to 25 May 2017 at an average price of €66.10.
19 May 2017
DSM repurchased 139,447 shares from 12 to 18 May 2017 at an average price of €66.66.
15 May 2017
Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.
12 May 2017
DSM repurchased 128,958 shares from 5 to 11 May 2017 at an average price of €65.76.
08 May 2017
DSM to make equity investment in Amyris and the companies to enter development cooperation focused on products for the health and nutrition markets.
05 May 2017
DSM repurchased 114,048 shares from 28 April to 4 May 2017 at an average price of €66.44.
03 May 2017
DSM declares a dividend for the financial year 2016 of €1.75 per ordinary share.
03 May 2017
DSM held its Annual General Meeting of Shareholders on 3 May 2017. Shareholders approved all resolutions on the agenda.
28 Apr 2017
DSM repurchased 126,540 shares from 21 to 27 April 2017 at an average price of €65.81.
21 Apr 2017
DSM repurchased 75,948 shares from 18 to 20 April 2017 at an average price of €65.02.
14 Apr 2017
DSM repurchased 126,073 shares from 7 to 13 April 2017 at an average price of €65.16.
07 Apr 2017
DSM repurchased 134,338 shares from 31 March to 6 April 2017 at an average price of €64.04.
31 Mar 2017
DSM repurchased 235,605 shares from 24 to 30 March 2017 at an average price of €62.81.
24 Mar 2017
DSM repurchased 308,025 shares from 17 to 23 March 2017 at an average price of €62.12.
21 Mar 2017
DSM proposes re-appointment of Dimitri de Vreeze the Managing Board and appointment of John Ramsay and Frits van Paasschen to the Supervisory Board.
17 Mar 2017
DSM repurchased 222,563 shares from 13 to 16 March 2017 at an average price of €62.92 for a total of €14.0 million.
13 Mar 2017
DSM to repurchase 2,900,000 ordinary shares to cover commitments under management and personnel option plans and for part of final dividend 2016.
03 Mar 2017
2016 Integrated Annual Report, in which DSM reports on its progress and performance over the year in terms of People, Planet and Profit, published on 3 March 2017.
15 Feb 2017
DSM reports a very good 2016 in which it achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in its Strategy 2018: Driving Profitable Growth.
14 Feb 2017
DSM updates way its financial results are presented starting with Q4/full-year results for 2016, following recent changes to accounting and reporting guidelines in Europe.
09 Dec 2016
DSM repurchased 361,907 shares from 2 to 8 December 2016 at an average price of €56.21 and concluded the program to repurchase 1,700,000 shares.
02 Dec 2016
DSM repurchased 215,424 of its own shares from 25 November to 1 December 2016 at an average price of €57.32.
25 Nov 2016
DSM repurchased 248,036 shares from 18 to 24 November 2016 at an average price of €57.14.
22 Nov 2016
DSM announces the departure of Managing Board and Executive Committee member Stephan B. Tanda as of 1 February 2017.
18 Nov 2016
DSM repurchased 360,149 shares from 11 to 17 November 2016 at an average price of €56.21.
11 Nov 2016
DSM repurchased 514,484 shares from 4 to 10 November 2016 at an average price of €56.17.
04 Nov 2016
DSM intends to repurchase up to 1,700,000 ordinary shares in order to cover its commitments under management and personnel option plans.
19 Sep 2016
DSM announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75%.
08 Sep 2016
DSM has been named the worldwide leader in the Materials industry group in the Dow Jones Sustainability World Index 2016.
27 Jul 2016
DSM announces the successful completion of its secondary offering of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.’s Initial Public Offering of ordinary shares.
22 Jul 2016
DSM repurchased 83,073 shares from 15 to 21 July 2016 at an average price of €56.75 and concluded the program to repurchase 3,500,000 shares.
21 Jul 2016
Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has priced its Initial Public Offering at USD 21.00 per ordinary share.
15 Jul 2016
DSM repurchased 107,432 shares from 8 to 14 July 2016 at an average price of €54.67.
11 Jul 2016
Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.
08 Jul 2016
DSM repurchased 95,055 shares from 1 to 7 July 2016 at an average price of €52.09.
01 Jul 2016
DSM repurchased 248,553 shares from 24 to 30 June 2016 at an average price of €50.64.
24 Jun 2016
DSM repurchased 115,202 shares from 17 to 23 June 2016 at an average price of €53.57.
17 Jun 2016
DSM repurchased 125,684 shares from 10 to 16 June 2016 at an average price of €53.20.
10 Jun 2016
DSM intends to increase the running share repurchase program by an additional 300,000 shares to a total of 3,500,000 to cover the interim stock dividend 2016.
03 Jun 2016
DSM repurchased 151,361 shares from 27 May to 2 June 2016 at an average price of €54.46.
27 May 2016
DSM repurchased 152,420 shares from 20 to 26 May 2016 at an average price of €53.26
20 May 2016
DSM repurchased 152,511 shares from 13 to 19 May 2016 at an average price of €52.54.
13 May 2016
DSM repurchased 153,360 shares from 6 to 12 May 2016 at an average price of €52.27.
06 May 2016
DSM repurchased 153,694 shares from 29 April to 5 May 2016 at an average price of €52.34.
03 May 2016
DSM provides an update on the development of its Nutrition organization and several key positions to further support its growth plans.
29 Apr 2016
DSM held its Annual General Meeting of Shareholders on 29 April 2016. Shareholders approved all resolutions on the agenda.
29 Apr 2016
DSM repurchased 163,523 shares from 22 to 28 April 2016 at an average price of €53.25.
29 Apr 2016
DSM declares a dividend for the financial year 2015 of €1.65 per ordinary share of €1.50 nominal value.
22 Apr 2016
DSM repurchased 153,579 shares from 15 to 21 April 2016 at an average price of €52.05.
15 Apr 2016
DSM repurchased 153,992 shares from 8 to 14 April 2016 at an average price of €50.01.
08 Apr 2016
DSM repurchased 167,229 shares from 1 to 7 April 2016 at an average price of €47.8951.
01 Apr 2016
DSM repurchased 93,033 shares from 29 to 31 March 2016 at an average price of €48.5712.
31 Mar 2016
All members of the Executive Committee purchase ordinary shares in Royal DSM, expressing their confidence in the growth prospects of the company.
25 Mar 2016
DSM repurchased 159,637 shares from 18 to 24 March 2016 at an average price of €48.28.
18 Mar 2016
DSM repurchased 161,667 shares from 11 to 17 March 2016 at an average price of €48.06.
11 Mar 2016
DSM repurchased 232,331 shares from 4 to 10 March 2016 at an average price of €47.13.
04 Mar 2016
DSM repurchased 269,930 shares from 26 February to 3 March 2016 at an average price of €45.84.
01 Mar 2016
DSM announces the publication of its 2015 Integrated Annual Report.
26 Feb 2016
DSM repurchased 267,680 shares from 22 to 25 February 2016 at an average price of €43.94.
25 Feb 2016
Ndidi Okonkwo Nwuneli, founder of LEAP Africa and co-founder of AACE Food Processing & Distribution Ltd and partner at Sahel Capital, an advisory and private equity firm, has joined DSM's Sustainability Advisory Board.
22 Feb 2016
DSM to repurchase 3,200,000 ordinary shares to cover commitments under management and personnel option plans and as part of the final dividend 2015.
17 Feb 2016
Q4 Group net sales up 6% to €1,926m and EBITDA up 3% to €261m.
07 Jan 2016
At the Annual General Meeting of Shareholders the Supervisory Board will nominate Mr. Pradeep Pant for appointment as a member of DSM's Supervisory Board.
06 Nov 2015
DSM and Syngenta R&D partnership to develop microbial-based agricultural solutions, including bio-controls, bio-pesticides and bio-stimulants.
04 Nov 2015
After a period of transformation, DSM will focus on improving its financial results through organic growth, reducing costs and strict capital allocation.
03 Nov 2015
Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange.
30 Oct 2015
DSM awarded FD-Henri Sijthoff prize for the best annual report by a company listed on the AEX stock exchange in the Netherlands for its 2014 Integrated Annual Report.
15 Sep 2015
DSM successfully issued a €500 million 1.375% bond due 2022.
10 Sep 2015
DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2015.
25 Aug 2015
Adjustments to organizational and operating model aim to create more agile, focused and cost efficient organization, with a stronger business and market focus and globally leveraged support functions.
04 Aug 2015
Solid sales performance with a 12% increase to €1,965 million, supported by foreign exchange rates and 3% volume growth.
31 Jul 2015
Partnership finalized for DSM’s activities in Polymer Intermediates (Caprolactam & Acrylonitrile) and Composite Resins with formation of ChemicaInvest B.V..
29 Jul 2015
DSM repurchased 204,254 shares from 24 to 28 July 2015 at an average price of €52.44 and concluded the program to repurchase 2,300,000 shares.
24 Jul 2015
DSM repurchased 184,648 shares from 17 to 23 July 2015 at an average price of €54.52.
17 Jul 2015
DSM repurchased 74,088 shares from 10 to 16 July 2015 at an average price of €53.54.
10 Jul 2015
DSM repurchased 190,870 shares from 3 to 9 July 2015 at an average price of €51.34.
03 Jul 2015
DSM repurchased 362,143 shares from 26 June to 2 July 2015 at an average price of €53.03.
26 Jun 2015
DSM repurchased 245,123 shares from 19 to 25 June 2015 at an average price of €53.87.
19 Jun 2015
DSM repurchased 223,561 shares from 12 to 18 June 2015 at an average price of €52.87.
12 Jun 2015
DSM repurchased 185,315 shares from 5 to 11 June 2015 at an average price of €53.36.
05 Jun 2015
DSM repurchased 277,686 shares from 29 May to 4 June 2015 at an average price of €53.95.
29 May 2015
DSM repurchased 128,219 shares from 22 to 28 May 2015 at an average price of €53.8102.
22 May 2015
DSM repurchased 224,093 shares from 18 to 21 May 2015 at an average price of €53.18.
14 May 2015
DSM intends repurchasing 2,300,000 ordinary shares in order to cover its commitments under management and personnel option plans.
30 Apr 2015
DSM declares dividend for the financial year 2014 of €1.65 per ordinary share.
30 Apr 2015
DSM held its Annual General Meeting of Shareholders on 30 April 2015. Shareholders approved all resolutions on the agenda.
29 Apr 2015
Sales of €1,886 million, up 11%, including 2% organic sales growth.
02 Apr 2015
DSM Synres produced solvent-borne alkyd and acrylic coating resins for the global coatings, adhesives and graphic arts markets.
02 Apr 2015
Figures reflect reclassification of Polymer Intermediates cluster and DSM Composite Resins to discontinued operations. Corporate Activities are restated and also reflect the sale of DSM Synres.
01 Apr 2015
DSM has successfully issued a €500 million 1.0% bond due 2025.
31 Mar 2015
DSM finalizes acquisition of Aland, a Hong Kong-based company producing vitamin C in mainland China.
18 Mar 2015
DSM proposes re-appointment of Stephan B. Tanda and announces departure of Stefan Doboczky as of 1 June 2015.
16 Mar 2015
Partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins with formation of new company 65% owned by CVC and 35% by DSM.
03 Mar 2015
Euroresins, a distributor of products to the composite resins industry, sold to Cathay Investments.
03 Mar 2015
DSM announces publication of 2014 Integrated Annual Report.
11 Feb 2015
Sales of €9,181 million, a 4% increase versus 2013. In line with market expectations, DSM reported EBITDA of €1,168 million compared to €1,261 million in 2013.
23 Dec 2014
DSM has reached agreement with Cathay Investments for the sale of Euroresins and the transaction is expected to close in Q1 2015.
17 Dec 2014
DSM has reached agreement with Standard Investment for the sale of DSM Synres and the transaction is expected to close in Q1 2015.
05 Nov 2014
DSM provides investors with update on its strategic progress and current priorities at annual Capital Markets Day.
04 Nov 2014
Third quarter 2014 EBITDA from continuing operations of €315 million compared to €293 million in Q2 2014 and €331 million in Q3 2013.
11 Sep 2014
DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2014.
03 Sep 2014
POET-DSM Advanced Biofuels proves its revolutionary technology that converts agricultural residue into renewable fuel at opening of its first commercial cellulosic ethanol plant.
05 Aug 2014
DSM's second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014.
11 Jul 2014
DSM reaches agreement to acquire Aland, a Hong Kong-based company producing vitamin C in mainland China.
02 Jul 2014
Production of a few intermediates, mainly for Animal Nutrition & Health interrupted. Impact on customers expected to be minimal.
20 May 2014
DSM repurchased 69,522 shares from 16 to 19 May 2014 at an average price of €51.67 and concluded the program to repurchase 5,000,000 shares.
16 May 2014
DSM repurchased 176,832 shares from 9 to 15 May 2014 at an average price of €51.97.
09 May 2014
DSM repurchased 294,921 shares from 2 to 8 May 2014 at an average price of €52.03.
07 May 2014
DSM declares dividend for the financial year 2013 of €1.65 per ordinary share.
07 May 2014
DSM held its Annual General Meeting of Shareholders on 7 May 2014. Shareholders approved all resolutions on the agenda.
06 May 2014
DSM reports first quarter EBITDA from continuing operations of €272 million compared to €301 million in Q1 2013.
02 May 2014
DSM repurchased 201,426 shares from 25 to 30 April 2014 at an average price of €51.49.
25 Apr 2014
DSM repurchased 170,120 shares from 22 to 24 April 2014 at an average price of €50.42.
18 Apr 2014
DSM repurchased 231,586 shares from 11 to 17 April 2014 at an average price of €49.15.
11 Apr 2014
DSM repurchased 256,801 shares from 4 to 10 April 2014 at an average price of €50.17.
09 Apr 2014
DSM in exclusive discussions with Aland that may or may not result in the acquisition of this China-based global producer of vitamin C.
04 Apr 2014
DSM repurchased 149,321 shares from 28 March to 3 April 2014 at an average price of €50.05.
28 Mar 2014
DSM repurchased 157,579 shares from 21 to 27 March 2014 at an average price of €48.46.
21 Mar 2014
DSM repurchased 108,500 shares from 14 to 20 March 2014 at an average price of €46.51.
14 Mar 2014
DSM repurchased 254,756 shares from 7 to 13 March 2014 at an average price of €47.40.
11 Mar 2014
USD 2.65 billion transaction to create global CDMO leader successfully completed.
10 Mar 2014
DSM to appoint Geraldine Matchett as Member of the Managing Board of Directors as of 1 August 2014 and as of 1 December 2014, she will become Chief Financial Officer.
07 Mar 2014
DSM repurchased 428,636 shares from 27 February to 6 March 2014 at an average price of €46.54.
27 Feb 2014
DSM intends to repurchase of 2,500,000 ordinary shares to cover commitments under management and personnel option plans.
26 Feb 2014
For full year 2013 DSM delivered 18% higher EBITDA while facing challenging economic environment. In Q4 the company realized 30% higher EBITDA.
23 Jan 2014
DSM repurchased 874,725 shares from 17 January 2014 up to and including 21 January 2014 at an average price of €51.85 and concludes first part of program to repurchase 4-5 million shares in total.
21 Jan 2014
DSM delivered roughly 20% higher EBITDA for the full year 2013, in spite of the challenging economic environment and in Q4 realized an approximately 30% higher EBITDA.
17 Jan 2014
DSM repurchased 245,742 shares from 10 to 16 January 2014 at an average price of €56.90.
10 Jan 2014
DSM repurchased 112,588 shares from 6 to 9 January 2014 at an average price of €57.88.
20 Dec 2013
DSM repurchased 154,586 shares from 13 to 19 December 2013 at an average price of €55.35.
18 Dec 2013
Final Terms of the €300,000,000 1.75% Notes due 13 November 2019 adjusted to reflect investors have a put option in the event of a change of control.
13 Dec 2013
DSM repurchased 185,761 shares from 6 to 12 December 2013 at an average price of €56.08.
06 Dec 2013
DSM repurchased 164,545 shares from 29 November to 5 December 2013 at an average price of €57.17.
21 Nov 2013
DSM repurchased 198,288 shares from 22 to 28 November 2013 at an average price of €58.39.
21 Nov 2013
DSM repurchased 346.038 shares from 15 to 21 November 2013 at an average price of €59.06.
19 Nov 2013
Global CDMO company combines DSM Pharmaceutical Products and Patheon.
15 Nov 2013
DSM repurchased 217,727 shares from 6 to 14 November 2013 at an average price of €58.05.
06 Nov 2013
DSM successfully issues €300 million 1.75% bond due 2019.
06 Nov 2013
DSM intends to repurchase 2,500,000 ordinary shares to cover commitments under management and personnel option plans.
05 Nov 2013
Q3 EBITDA of €342 million compared to €270 million in Q3 2012. 27% improvement realized despite ongoing challenging macro-economic environment.
09 Oct 2013
DSM acquires 19% equity interest in Yantai Andre Pectin Co. Ltd., a China based producer of texturing ingredients.
26 Sep 2013
DSM providing review of strategic progress and update on its 2015 targets at its annual Capital Markets Day.
12 Sep 2013
DSM once again amongst leaders in chemical industry sector in Dow Jones Sustainability World Index 2013.
06 Aug 2013
DSM reports second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013.
01 Jul 2013
DSM acquires Unitech Industries Limited, a New Zealand based producer of nutritional products for both human and animal markets.
07 May 2013
Agreement to acquire 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients.
03 May 2013
DSM declares a dividend for the financial year 2012 of €1.50 per ordinary share of €1.50 nominal value.
03 May 2013
DSM held its Annual General Meeting of Shareholders on 3 May 2013. Shareholders approved all resolutions on the agenda.
02 May 2013
DSM reports first quarter EBITDA of €311 million compared to €306 million in Q1 2012 and €243 million in Q4 2012.
08 Apr 2013
Strategic partnership with Rostekhnologii (Rostec) in fields of biotechnology and functional materials.
08 Apr 2013
Partnership with Ministry of Health Care of the Republic of Tatarstan aims to modernize the Republic’s public health sector through fortified nutrition.
08 Apr 2013
DSM acquires Tortuga, a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million.
14 Mar 2013
DSM proposes appointing Mr. Dimitri de Vreeze to the Managing Board effective 1 September 2013.
04 Mar 2013
DSM sells its participation in DEXPlastomers, a 50/50 Joint Venture of DSM with affiliate of ExxonMobil Chemical, to Borealis.
20 Feb 2013
DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.
19 Dec 2012
Completing acquisition of Fortitech is another milestone in implementation of DSM’s Nutrition strategy.
06 Dec 2012
Acquisition enables DSM to become a global tier one dairy ingredients supplier.
23 Nov 2012
DSM receives three prestigious awards in the Netherlands for its 2011 Integrated Annual Report.
12 Nov 2012
Agreement with Borealis AG reached for sale of DEXPlastomers V.o.F and DSM's LldPE Compact Solution Technology.
08 Nov 2012
Definitive agreement to acquire Fortitech, Inc. (Fortitech) in an all cash transaction for a total enterprise value of $634 million.
06 Nov 2012
DSM continues to generate good results mainly driven by Nutrition cluster and make good progress towards strategic goals with purchase of Tortuga and Cargill’s cultures and enzymes business.
26 Oct 2012
DSM to acquire Cargill’s cultures and enzymes business in an all cash transaction for a total enterprise value of €85 million.
27 Sep 2012
DSM updates financial community at its annual Capital Markets Days on progress made with its DSM in Motion: driving focused growth strategy.
20 Sep 2012
Chris Goppelsroeder appointed President and CEO DSM Nutritional Products effective 1 January 2013.
20 Sep 2012
DSM in exclusive discussions with Cargill which may, or may not result in DSM's acquisition of Cargill’s cultures and enzymes business.
13 Sep 2012
DSM again among leaders in chemical industry sector in the Dow Jones Sustainability World Index 2012.
08 Aug 2012
Definitive agreement to acquire Tortuga Companhia Zootécnica Agrária (Tortuga) in all cash transaction for total enterprise value of about €465 million.
07 Aug 2012
Life Sciences cluster accounts for around 70% of Q2 EBITDA offsetting weakness caused by caprolactam in Materials Sciences. Other Materials Sciences businesses improve.
19 Jul 2012
DSM acquires Ocean Nutrition Canada, leading global provider of fish-oil derived nutritional products to dietary supplement and food and beverage markets for a total enterprise value of C$540 million.
25 Jun 2012
DSM completes acquisition of Kensey Nash for a total enterprise value of approximately $360 million.
19 Jun 2012
Tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation at a price of $38.50 per share successful.
06 Jun 2012
Expiration of mandatory waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation.
05 Jun 2012
DSM qualified as supplier of enzymes for DONG Energy - Inbicon’s wheat straw to cellulosic ethanol process.
21 May 2012
DSM commences previously announced tender offer for all outstanding shares of common stock of Kensey Nash at a price of $38.50 per share.
18 May 2012
Definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of C$540 million.
11 May 2012
Annual General Meeting of Shareholders approves appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.
11 May 2012
DSM declares a dividend for 2011 of €1.45 per ordinary share of €1.50 par value.
11 May 2012
DSM held its Annual General Meeting of Shareholders on 11 May 2012. Shareholders approved all resolutions on the agenda.
08 May 2012
In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.
03 May 2012
DSM will acquire all outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 in cash per share for total enterprise value of approximately $360 million.
01 May 2012
Jos Op Heij new Senior Vice President Corporate Control and Accounting, Hans Vossen new VP Corporate Treasury & Dave Huizing new VP Investor Relations.
26 Mar 2012
DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of $37 million.
29 Feb 2012
2011 was another strong year for DSM despite challenges of global economy, adverse currency movements and high raw material costs and increases dividend for second consecutive year.
14 Feb 2012
Cees Los joins DSM as General Counsel and Director Legal Affairs as of 15 April 2012.
23 Jan 2012
Joint Venture to commercially demonstrate and license cellulosic bio-ethanol, the next step in the development of biofuels, based on their proprietary and complementary technologies.
DSM's Factbook provides investors and analysts with an introduction to the company and our key individual businesses.
An overview of DSM's key financial events for the next 12 months.
An introduction to DSM's Investor Relations team and how investors and analysts can contact them.
